In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lessons Learned: David Perry, from Chemdex to Anacor

This article was originally published in Start Up

Executive Summary

Six years ago, David Perry was one of the rock stars of the Web, the founding CEO of Chemdex-Ventro. He stuck with it as the company unraveled, shutting down most of the businesses he'd built, and merging the remainder into what is now an OTC-traded software company. Now he's applying the lessons he learned to his current company, Anacor Pharmaceuticals, a start-up which has discovered a small handful of now clinical-stage compounds.

You may also be interested in...



After Pulling IPO, Anacor Raises $50 Million In Equity Financing

Boron compound-focused biotech says proceeds should fund two years of operations.

After Pulling IPO, Anacor Raises $50 Million In Equity Financing

Boron compound-focused biotech says proceeds should fund two years of operations.

Anacor Pharmaceuticals Inc.

Anacor Pharmaceuticals Inc. is developing a new class of antibiotics against a novel target discovered by its scientific founders. The company aims to create drugs that will address the growing problem of bacterial resistance to existing antibiotics, and also for use against biowarfare pathogens, such as anthrax, likely to be deployed in a bioterror attack.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel